Answers are grounded in this paper and cite their sources.
Database analysis reveals comparable three-year survival across three ex vivo lung perfusion platforms in lung transplant recipients, indicating flexible preservation options.
We thank Drs Gouchoe and Whitson1 from the Ohio State University for their insightful comments on our article. We agree with many of their comments. As they observe in their editorial “Compare apples to apples,” our data suggest there are no significant outcomes differences between the currently available ex vivo lung perfusion (EVLP) strategies.2 Three EVLP platforms are currently used to screen high-risk donors but have also been incorporated into surgical preservation strategy to accommodate for logistics and reduction of cold ischemic times. It is worth mentioning that each EVLP platform was originally designed with a specific purpose.3,4 Briefly, mobile-EVLP was initially designed with the goal of minimizing cold ischemia, and external-EVLP-facilities goal was to formalize perfusion and evaluation protocols while helping programs that do not have sufficient perfusion volumes or personnel to justify a hospital-EVLP effort. With these differences in mind, any research that cannot accurately capture the programmatic reason behind the use of particular EVLP strategies will always be comparing “apples to oranges.” By using a combination of currently available national data, we were able to determine whether the donor lungs were perfused by an external-EVLP-facilities or hospital-EVLP. Then, we were able to determine whether the lungs were received on ice or pumped/perfused. This allowed us to clearly define 3 perfusion strategies: mobile-EVLP, hospital-EVLP, and external-EVLP-facilities.5 In our opinion, this methodological approach facilitates comparisons across platforms, allowing the query of national data into evolving EVLP practices. We would also like to clarify the perfusate concerns raised by the authors. In the United States, there are only 2 Federal Drug Administration–approved devices with very specific perfusion protocols. The XVIVO-XPS device is used by hospital-EVLP and external-EVLP-facilities, and the TransMedics Organ Care System Lung Technology is used as mobile-EVLP. Although the United Network for Organ Sharing database does not specifically capture the perfusate type used, all ex vivo perfusions were performed under Federal Drug Administration protocols, guaranteeing the use of approved perfusion solutions for each methodology. It is worth noting that the mobile-EVLP platform uses a red cell–based perfusate, whereas the hospital-EVLP and external-EVLP-facilities use an acellular solution.3 Our study demonstrates that, even with the inherent variability in donation after circulatory determination of death and EVLP practices, survival outcomes at 3 y were comparable across platforms. We agree with the call for further studies to explore perfusate types and long-term outcomes. We also recognize the importance of increasing the granularity within the United Network for Organ Sharing database to be able to better answer some of these questions. As we continue to move forward, collaboration among transplant centers and regulatory bodies is essential to ensure equitable and effective practices in EVLP and donation after circulatory determination of death lung transplantation. Until then, the data we present is “as good as it gets.”
No takes yet. Share an insight, caveat, or question.
Alzahrani et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: